FTY720 - a novel immunomodulator - Efficacy and safety results from the first phase 2a study in de novo renal transplantation

Autor: Barry D. Kahan, Shamkant Mulgaonkar, Søren Madsen, Helio Tedesco-Silva, Josep Grinyo Boira, Willem Weimar, Georges Mourad, Björn Nashan, Bernard Charpentier, Yves Vanrenterghem, Pascale Pellet

Publikováno v: Transplantation, 77(12), 1826-1833. Lippincott Williams & Wilkins
Madsen, S, Tedesco-Silver, H, Mourad, G, Kahan, B D, Boira, J G, Weimar, W, Mulgaonkar, S, Nashan, B, Charpentier, B, Pellet, P & Vanrenterghem, Y 2005, ' FTY720, a novel immunomodulator: Efficacy and safety results from the first phase 2A study in de novo renal transplantation. ' Transplantation, vol. 79, pp. 1553-1560 .
Tedesco-Silva, H, Mourad, G, Kahan, B D, Boira, J G, Weimar, W, Mulgan, S, Nashan, B, Madsen, S, Charpentier, B, Pellet, P & Vanrenterghem, Y 2004, ' FTY-720, a novel immunomodulator: efficacy and safety results from the first phase 2a study in de novo renal transplantation ', Transplantation, no. 77, pp. 1826-1833 .

BACKGROUND FTY720 is the first of a new drug class: sphingosine-1-phosphate receptor agonist. Its effect relates to the modulation of lymphocytes trafficking from blood and peripheral tissues to lymph nodes. This is the first study to evaluate the ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3207b1d2c45943339101e6f1bca114bb
https://pure.eur.nl/en/publications/91a5edf3-4ffa-49a2-8dc0-73986ff05834